跳至主要内容
临床试验/EUCTR2020-001084-83-FR
EUCTR2020-001084-83-FR进行中(未招募)1 期

rea treatment of hyponatremia during subarachnoid hemorrhage - NAT-URE

CHU Grenoble-Alpes0 个研究点目标入组 52 人开始时间: 2020年4月10日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
52

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Patients at least 18 years old
  • - Non-traumatic subarachnoid hemorrhage
  • - Hyponatremia defined by a serum lower than 135
  • mmol / L and high natriuresis, greater than 250 mmol / L
  • despite well-conducted salt additions
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 52
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 52

排除标准

  • - Severe cardiac decompensation (LVEF <30%)
  • - Severe hepatic cirrhosis (PT <30%, ascites), insufficiency
  • known severe renal (GFR <30mL / min / 1.73m²)
  • - Blood urea> 25 mmol / L in the basal state
  • - Osmotherapy and diuretics in the last 48 hours
  • - Ongoing treatment with systemic corticosteroids
  • - All protected persons: woman pregnant, parturient, nursing mother, person deprived of liberty by judicial or administrative decision, person making subject to legal protection.
  • - Patient not affiliated to a social security scheme
  • - Known hypersensitivity to any of the components of energytonyl
  • - Contraindications to energytonyl: taking anticoagulants,
  • diabetic patients treated

研究者

发起方
CHU Grenoble-Alpes

相似试验